Oppenheimer Asset Management Inc. Mirati Therapeutics, Inc. Transaction History

Oppenheimer Asset Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$27.8 - $45.35 $63,856 - $104,168	2,297 Added 27.98%	10,507 $457,000
Q2 2023 Aug 02, 2023	SELL	$36.13 - $49.49 $17,956 - $24,596	-497 Reduced 5.71%	8,210 $296,000
Q1 2023 May 10, 2023	BUY	$36.54 - $54.26 $53,202 - $79,002	1,456 Added 20.08%	8,707 $323,000
Q4 2022 Feb 06, 2023	SELL	$41.27 - $98.62 $14,403 - $34,418	-349 Reduced 4.59%	7,251 $328,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $12,435 - $18,120	-209 Reduced 2.68%	7,600 $531,000
Q2 2022 Aug 08, 2022	BUY	$39.16 - $88.71 $151,118 - $342,331	3,859 Added 97.7%	7,809 $524,000
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $299,489 - $596,331	3,950 New	3,950 $325,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.